Evaluating pathogenicity of variants of unknown significance in APP, PSEN1, and PSEN2

IF 6.9 2区 医学 Q1 CLINICAL NEUROLOGY Neurotherapeutics Pub Date : 2025-04-01 DOI:10.1016/j.neurot.2025.e00527
Jacob A. Marsh , Guangming Huang , Kevin Bowling , Alan E. Renton , Ellen Ziegemeier , Torri Ball , Cyril Pottier , Carlos Cruchaga , Gregory S. Day , Randall J. Bateman , Jorge J. Llibre-Guerra , Eric McDade , Celeste M. Karch
{"title":"Evaluating pathogenicity of variants of unknown significance in APP, PSEN1, and PSEN2","authors":"Jacob A. Marsh ,&nbsp;Guangming Huang ,&nbsp;Kevin Bowling ,&nbsp;Alan E. Renton ,&nbsp;Ellen Ziegemeier ,&nbsp;Torri Ball ,&nbsp;Cyril Pottier ,&nbsp;Carlos Cruchaga ,&nbsp;Gregory S. Day ,&nbsp;Randall J. Bateman ,&nbsp;Jorge J. Llibre-Guerra ,&nbsp;Eric McDade ,&nbsp;Celeste M. Karch","doi":"10.1016/j.neurot.2025.e00527","DOIUrl":null,"url":null,"abstract":"<div><div>Autosomal dominant Alzheimer's disease (ADAD) is driven by rare variants in <em>APP</em>, <em>PSEN1</em>, and <em>PSEN2</em>. Although more than 200 pathogenic variants in these genes are known to cause ADAD, other variants are benign, may act as risk factors, or may even reduce Alzheimer's disease risk (e.g. protective). Classifying novel variants in <em>APP</em>, <em>PSEN1</em>, or <em>PSEN2</em> as pathogenic, risk, benign, or protective is a critical step in evaluating disease risk profiles which further impacts eligibility for clinical trials focused on the ADAD population. Here, we classify 53 novel variants in <em>APP</em>, <em>PSEN1</em>, and <em>PSEN2</em> based on bioinformatic data and cell-based assays. We identified 6 benign variants, 2 risk variants, and 32 likely pathogenic variants. Thirteen variants were associated with reduced Aβ levels in cell-based assays, consistent with a potential protective effect. Together, this study highlights the complexities associated with classification of rare variants in ADAD genes.</div></div>","PeriodicalId":19159,"journal":{"name":"Neurotherapeutics","volume":"22 3","pages":"Article e00527"},"PeriodicalIF":6.9000,"publicationDate":"2025-04-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Neurotherapeutics","FirstCategoryId":"3","ListUrlMain":"https://www.sciencedirect.com/science/article/pii/S1878747925000054","RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q1","JCRName":"CLINICAL NEUROLOGY","Score":null,"Total":0}
引用次数: 0

Abstract

Autosomal dominant Alzheimer's disease (ADAD) is driven by rare variants in APP, PSEN1, and PSEN2. Although more than 200 pathogenic variants in these genes are known to cause ADAD, other variants are benign, may act as risk factors, or may even reduce Alzheimer's disease risk (e.g. protective). Classifying novel variants in APP, PSEN1, or PSEN2 as pathogenic, risk, benign, or protective is a critical step in evaluating disease risk profiles which further impacts eligibility for clinical trials focused on the ADAD population. Here, we classify 53 novel variants in APP, PSEN1, and PSEN2 based on bioinformatic data and cell-based assays. We identified 6 benign variants, 2 risk variants, and 32 likely pathogenic variants. Thirteen variants were associated with reduced Aβ levels in cell-based assays, consistent with a potential protective effect. Together, this study highlights the complexities associated with classification of rare variants in ADAD genes.
查看原文
分享 分享
微信好友 朋友圈 QQ好友 复制链接
本刊更多论文
评估APP、PSEN1和PSEN2中未知变异的致病性。
常染色体显性阿尔茨海默病(ADAD)是由APP、PSEN1和PSEN2的罕见变异驱动的。虽然已知这些基因中有200多种致病变异会导致ADAD,但其他变异是良性的,可能是风险因素,甚至可能降低阿尔茨海默病的风险(例如保护性)。将APP、PSEN1或PSEN2的新变异分类为致病性、风险性、良性或保护性是评估疾病风险概况的关键步骤,这将进一步影响针对ADAD人群的临床试验的资格。在这里,我们根据生物信息学数据和基于细胞的分析,对APP、PSEN1和PSEN2的53个新变体进行了分类。我们确定了6个良性变异,2个危险变异和32个可能的致病变异。在基于细胞的检测中,13个变异与降低的a β水平相关,这与潜在的保护作用一致。总之,这项研究强调了与ADAD基因罕见变异分类相关的复杂性。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 去求助
来源期刊
Neurotherapeutics
Neurotherapeutics 医学-神经科学
CiteScore
11.00
自引率
3.50%
发文量
154
审稿时长
6-12 weeks
期刊介绍: Neurotherapeutics® is the journal of the American Society for Experimental Neurotherapeutics (ASENT). Each issue provides critical reviews of an important topic relating to the treatment of neurological disorders written by international authorities. The Journal also publishes original research articles in translational neuroscience including descriptions of cutting edge therapies that cross disciplinary lines and represent important contributions to neurotherapeutics for medical practitioners and other researchers in the field. Neurotherapeutics ® delivers a multidisciplinary perspective on the frontiers of translational neuroscience, provides perspectives on current research and practice, and covers social and ethical as well as scientific issues.
期刊最新文献
Network-based prediction and real-world patient data observation identify doxycycline as a repurposable drug in Alzheimer's disease. KITENIN-CCL20 axis is a potential therapeutic target for modulating immunosuppressive tumor microenvironment in glioblastoma. Heterogeneous Deep Gray Matter Iron Deposition Patterns across Multiple Sclerosis Subgroups Defined by the Clinico-Radiological Paradox. Advances in Treatment of Psychiatric Disorders in Patients with HIV. Neuron-glioma synaptic transmission amplified by free 19S proteasome-mediated AMPAR deubiquitination promotes tumor progression.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
0
微信
客服QQ
Book学术公众号 扫码关注我们
反馈
×
意见反馈
请填写您的意见或建议
请填写您的手机或邮箱
已复制链接
已复制链接
快去分享给好友吧!
我知道了
×
扫码分享
扫码分享
Book学术官方微信
Book学术文献互助
Book学术文献互助群
群 号:604180095
Book学术
文献互助 智能选刊 最新文献 互助须知 联系我们:info@booksci.cn
Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。
Copyright © 2023 Book学术 All rights reserved.
ghs 京公网安备 11010802042870号 京ICP备2023020795号-1